Literature DB >> 21257927

Fas activation in alveolar epithelial cells induces KC (CXCL1) release by a MyD88-dependent mechanism.

Alex W Farnand1, Alison J Eastman, Raquel Herrero, Josiah F Hanson, Steve Mongovin, William A Altemeier, Gustavo Matute-Bello.   

Abstract

Activation of the Fas/Fas ligand (FasL) system is associated with activation of apoptotic and proinflammatory pathways that lead to the development of acute lung injury. Previous studies in chimeric mice and macrophage-depleted mice suggested that the main effector cell in Fas-mediated lung injury is not a myeloid cell, but likely an epithelial cell. The goal of this study was to determine whether epithelial cells release proinflammatory cytokines after Fas activation, and to identify the relevant pathways. Incubation of the murine alveolar epithelial cell line, MLE-12, with the Fas-activating monoclonal antibody, Jo2, resulted in release of the CXC chemokine, KC, in a dose-dependent manner. KC release was not prevented by the pan-caspase inhibitor, zVAD.fmk. Silencing of the adaptor protein, MyD88, with small interfering (si)RNA resulted in attenuation of KC release in response to Jo2. Fas activation resulted in phosphorylation of the mitogen-activated kinases extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK), and pharmacologic inhibition of ERK and JNK attenuated KC release in a dose-response manner. Similarly, primary human small airways epithelial cells released IL-8 in response to soluble FasL, and this was abrogated by inhibition of JNK and ERK. In vivo confirmatory studies showed that MyD88-null mice are protected from Fas-induced acute lung injury. In summary, we conclude that Fas induces KC release in MLE-12 cells by a mechanism requiring MyD88, mitogen-activated protein kinases, and likely activator protein-1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257927      PMCID: PMC3175574          DOI: 10.1165/rcmb.2010-0153OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  38 in total

1.  IL-13 and TH2 cytokine exposure triggers matrix metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial cells.

Authors:  Samuel J Wadsworth; Ryo Atsuta; J Oliver McIntyre; Tillie-Louise Hackett; Gurpreet K Singhera; Delbert R Dorscheid
Journal:  J Allergy Clin Immunol       Date:  2010-07-10       Impact factor: 10.793

2.  The Fas-associated death domain protein suppresses activation of NF-kappa B by LPS and IL-1 beta.

Authors:  Douglas D Bannerman; Joan C Tupper; James D Kelly; Robert K Winn; John M Harlan
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

3.  Daxx, a novel Fas-binding protein that activates JNK and apoptosis.

Authors:  X Yang; R Khosravi-Far; H Y Chang; D Baltimore
Journal:  Cell       Date:  1997-06-27       Impact factor: 41.582

4.  Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.

Authors:  D Siegmund; D Mauri; N Peters; P Juo; M Thome; M Reichwein; J Blenis; P Scheurich; J Tschopp; H Wajant
Journal:  J Biol Chem       Date:  2001-05-30       Impact factor: 5.157

Review 5.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

6.  Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis.

Authors:  Keu Sung Lee; Young Hwa Choi; Young Sun Kim; Seung Hee Baik; Yoon Jung Oh; Seung Soo Sheen; Joo Hun Park; Sung Chul Hwang; Kwang Joo Park
Journal:  Respir Med       Date:  2007-11-07       Impact factor: 3.415

7.  Fas-ligand-induced apoptosis of respiratory epithelial cells causes disruption of postcanalicular alveolar development.

Authors:  Monique E De Paepe; Sravanthi Gundavarapu; Umadevi Tantravahi; John R Pepperell; Sheila A Haley; Francois I Luks; Quanfu Mao
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

8.  Recent trends in acute lung injury mortality: 1996-2005.

Authors:  Sara E Erickson; Greg S Martin; J Lucian Davis; Michael A Matthay; Mark D Eisner
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

9.  Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury.

Authors:  Colin R Cooke; Jeremy M Kahn; Timothy R Watkins; Leonard D Hudson; Gordon D Rubenfeld
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

Review 10.  Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review.

Authors:  Jason Phua; Joan R Badia; Neill K J Adhikari; Jan O Friedrich; Robert A Fowler; Jeff M Singh; Damon C Scales; David R Stather; Amanda Li; Andrew Jones; David J Gattas; David Hallett; George Tomlinson; Thomas E Stewart; Niall D Ferguson
Journal:  Am J Respir Crit Care Med       Date:  2008-11-14       Impact factor: 21.405

View more
  14 in total

1.  Death receptors mediate the adverse effects of febrile-range hyperthermia on the outcome of lipopolysaccharide-induced lung injury.

Authors:  Anne B Lipke; Gustavo Matute-Bello; Raquel Herrero; Venus A Wong; Stephen M Mongovin; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-22       Impact factor: 5.464

Review 2.  Cytokine-Ion Channel Interactions in Pulmonary Inflammation.

Authors:  Jürg Hamacher; Yalda Hadizamani; Michèle Borgmann; Markus Mohaupt; Daniela Narcissa Männel; Ueli Moehrlen; Rudolf Lucas; Uz Stammberger
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

3.  Role of the Fas/FasL system in a model of RSV infection in mechanically ventilated mice.

Authors:  Elske van den Berg; Job B M van Woensel; Albert P Bos; Reinout A Bem; William A Altemeier; Sean E Gill; Thomas R Martin; Gustavo Matute-Bello
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-08       Impact factor: 5.464

4.  Myeloperoxidase deficiency in mice exacerbates lung inflammation induced by nonviable Candida albicans.

Authors:  Mizuki Homme; Nao Tateno; Noriko Miura; Naohito Ohno; Yasuaki Aratani
Journal:  Inflamm Res       Date:  2013-08-18       Impact factor: 4.575

5.  p120-catenin expressed in alveolar type II cells is essential for the regulation of lung innate immune response.

Authors:  Andreia Z Chignalia; Stephen M Vogel; Albert B Reynolds; Dolly Mehta; Randal O Dull; Richard D Minshall; Asrar B Malik; Yuru Liu
Journal:  Am J Pathol       Date:  2015-03-13       Impact factor: 4.307

6.  The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancya.

Authors:  Ichchha Madan; Nandor Gabor Than; Roberto Romero; Piya Chaemsaithong; Jezid Miranda; Adi L Tarca; Gaurav Bhatti; Sorin Draghici; Lami Yeo; Moshe Mazor; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Perinat Med       Date:  2014-01       Impact factor: 1.901

7.  The Fas/FasL pathway impairs the alveolar fluid clearance in mouse lungs.

Authors:  Raquel Herrero; Mishie Tanino; Lincoln S Smith; Osamu Kajikawa; Venus A Wong; Steve Mongovin; Gustavo Matute-Bello; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-06-28       Impact factor: 5.464

Review 8.  Life in the Fas lane: differential outcomes of Fas signaling.

Authors:  Elizabeth Brint; Grace O'Callaghan; Aileen Houston
Journal:  Cell Mol Life Sci       Date:  2013-04-12       Impact factor: 9.261

9.  Fas activation alters tight junction proteins in acute lung injury.

Authors:  Raquel Herrero; Lucia Prados; Antonio Ferruelo; Ferranda Puig; Rachele Pandolfi; Raquel Guillamat-Prats; Laura Moreno; Gustavo Matute-Bello; Antonio Artigas; Andres Esteban; José Ángel Lorente
Journal:  Thorax       Date:  2018-11-01       Impact factor: 9.139

10.  The bioactivity of soluble Fas ligand is modulated by key amino acids of its stalk region.

Authors:  Osamu Kajikawa; Raquel Herrero; Yu-Hua Chow; Chi F Hung; Gustavo Matute-Bello
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.